Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services, signed a letter of intent to develop and license formulation packages…
Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.
Noramco welcomes enquiries from the news media.
Whether you are looking for basic company information or have a follow up question regarding a recent press release, we are here to help. During regular business hours (8:00AM-5:30PM EST, M-F) members of the media should call our corporate headquarters.
A major producer of specialty APIs for the pharmaceutical industry, Noramco is qualified to provide commentary in a number of topic areas, including API research and development, reference standards, and custom synthesis. For assistance, contact us.